Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate ACN Newswire

Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC ACN Newswire

Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
「戰爭追著我們不放」:敘利亞家庭逃離以色列轟炸的貝魯特,卻在家鄉面臨鎮壓和轟炸 News

「戰爭追著我們不放」:敘利亞家庭逃離以色列轟炸的貝魯特,卻在家鄉面臨鎮壓和轟炸

(SeaPRwire) - 艾哈邁德·亞希亞·達巴斯十多年前逃往黎巴嫩,以逃避敘利亞總統巴沙爾·阿薩德政權及其俄羅斯盟友在敘利亞西北部持續不斷的轟炸和頻繁空襲。37歲的達巴斯搬到了貝魯特南部郊區,在那裡他找到了一份門衛的工作,並開始重建遠離飽受戰爭蹂躪的祖國的新生活。他和妻子迎來了四個孩子,兩個男孩和兩個女孩,現在年齡在4到9歲之間。隨著以色列在9月下旬開始報復行動,在他們的家被摧毀後,這家人決定搬回敘利亞。達巴斯通過電話接受了數位新聞的採訪,採訪地點位於敘利亞西北部,由位於華盛頓特區的非營利倡導組織敘利亞緊急工作隊 (SETF) 提供翻譯,他在採訪中描述了他家從黎巴嫩到阿薩德政權控制區以外地區的為期五天的旅程,以及他們作為流離失所者所面臨的挑戰。「我們去了黎巴嫩,戰爭卻追隨著我們,”他說。“出於同樣的原因,我們不得不放棄一切以尋找安全。因此,我們不得不從黎巴嫩逃回敘利亞。」一旦這家人到達敘利亞-黎巴嫩邊境,他們就遇到了許多由阿薩德政權的各種安全機構把守的檢查站。達巴斯說,許多檢查站的工作人員要求他們支付通行費,他們最終不得不支付賄賂才能繼續前進。這家人經過一個又一個檢查站,最終到達阿勒頗市。當他們到達時,已經很晚了,所以他們在那裡過了一夜,然後前往一個進入非政權控制區的過境點。然後,他們在阿勒頗政權控制區和反叛軍控制區之間的“無人區”待了三個晚上。達巴斯說,在他們等待期間,他們遭到唾棄、毆打,而且不允許吃喝,其他從黎巴嫩逃離並試圖離開政權控制區的人也是如此。他補充說,過了兩天才得到食物。他們最終到達了邊境的反叛軍一方,在一個檢查站待了一天,然後終於在10月4日在反對派地區登記並定居在伊德利卜北部鄉村。達巴斯一家是許多選擇逃往敘利亞非政權控制區的人之一,他們在敘利亞政府手中遭受酷刑、強行失踪甚至死亡的威脅。SETF執行董事穆阿茲·穆斯塔法告訴數位新聞,一些海灣阿拉伯國家與阿薩德政權恢復正常關係,一些歐洲國家正在考慮強制遣返敘利亞難民,這“令人害怕”且“令人不安”。“敘利亞並不安全,”穆斯塔法說。“在任何政權控制區,人們寧願繼續走下去,即使他們已經走了很長時間。”聯合國難民署表示,有超過47萬人——其中約30%是黎巴嫩人,70%是敘利亞人——從黎巴嫩越境進入敘利亞,以逃離以色列的轟炸。在經歷了一年多的跨境衝突後,以色列在9月份加強了對真主黨恐怖組織的轟炸行動,這些衝突始於2023年10月7日哈馬斯在以色列南部發動恐怖襲擊的第二天。以色列消滅了該恐怖組織的幾名知名領導人,包括長期擔任真主黨領導人的哈桑·納斯魯拉和高級指揮官易卜拉欣·阿基爾,後者懸賞金額來自美國國務院。儘管以色列和黎巴嫩在11月下旬達成停火協議,但達巴斯說他和家人不會返回貝魯特。這位四個孩子的父親說,他的兄弟也在敘利亞西北部流離失所,一直在幫助他們,但他們到來時收到的食物已經用完了,而且他正在努力找工作。他們與其他在2014年未能逃離敘利亞並逃離阿薩德政權、俄羅斯和伊朗支持的部隊的大家庭成員住在一間擁擠的房子裡。“沒有安全和保障,”達巴斯說。他告訴數位新聞,回到祖國,與家人團聚,他感到一種難以言喻的喜悅,但他希望和平到來,轟炸停止。敘利亞西北部的 гуманітарна криза近幾個月來日益惡化,流離失所者人數增加,以及對居民區平民的無人機襲擊激增。聯合國人道事務協調廳估計,敘利亞西北部有350萬流離失所者,其中200萬人居住在難民營。敘利亞民防組織(也稱為白頭盔)志願者伊斯梅爾·阿卜杜拉也告訴數位新聞,該組織是一個在敘利亞內戰開始後的2013年成立的救援組織,阿薩德政權及其盟友開始了一種新的策略,即用自殺式無人機襲擊居民區。阿卜杜拉說,自11月10日以來,白頭盔團隊已經應對了876次襲擊。目標是平民設施,例如農場、城鎮和農業區以及民用基礎設施。“老實說,這種武器,自殺式無人機,非常非常危險,”他說。“它們很便宜,可以隨意飛行。它們可以攻擊任何它們想要攻擊的地方。”“家長害怕送孩子去上學,”阿卜杜拉補充道。“也許世界仍然——他們不想聽到這個。他們想聽到轟炸已經停止,敘利亞沒有發生任何事情,敘利亞西北部是安全的。它並不安全。襲擊仍在繼續,尤其是在伊德利卜。”敘利亞政權軍隊及其盟友近幾個月在阿勒頗西部和伊德利卜東部發動攻勢,導致數百個家庭流離失所。令人驚訝的是,敘利亞反叛軍在本周早些時候對政權軍隊發動攻勢後,於週五首次自2016年以來進入該國第二大城市阿勒頗。路透社指出,自2020年以來,這是首次領土推進,此前土耳其和俄羅斯之間的停火協議停止了在伊德利卜的戰鬥。阿卜杜拉告訴數位新聞,白頭盔仍然需要國際社會的幫助,而且需求超過了他們的能力,尤其是在冬季即將來臨,他們要應對越來越多的流離失所者。“我们需要每个人都站在我们这边,制止暴行,制止杀戮,”他说。“想象一下。他们不知道钥匙是什么。直到现在,他们还没有见过带钥匙的门,他们不知道这是他们房子的门。”“这一切都必须停止。人们需要回到家园,结束苦难,重新过上自己的生活。”本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
校車司機被控囚禁女童12年 News

校車司機被控囚禁女童12年

(SeaPRwire) - 檢察官透露,一名男子涉嫌綁架一名7歲女童,並囚禁她十多年,直到今年稍早她才逃脫。據哥倫比亞麥德林的檢察官說,這名嫌犯,身份證實為卡洛斯·翁貝托·格里薩萊斯·伊吉塔,目前被控犯下簡單綁架罪、對未滿14歲的未成年人實施性侵犯罪、與未滿14歲的未成年人發生性行為罪以及製作未滿18歲人士的色情作品罪。「這名男子曾擔任校車司機,據稱在2012年初將一名7歲女童拘留並帶到市中心的住所,」檢察官說。「他據稱對她進行心理操縱和性侵犯,讓她相信這種行為是正常的。」調查人員表示,在受害者被囚禁期間,她的名字被更改了,她被帶到麥德林和貝約各城市的許多建築物,並且沒有上學。 檢察官說:「當她16歲時,她向涉嫌的施暴者抱怨她受到的待遇,作為報復,她據稱被關押在一所房子裡,她於今年2月設法從那裡逃脫。」他們還表示,受害者12年前最初失蹤。 「格里薩萊斯·伊吉塔被麥德林國家警察逮捕,」檢察官說。「在初步聽證會上,他沒有認罪。」格里薩萊斯·伊吉塔仍被當地當局拘留。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
英國議員投票贊成協助安樂死法案
“` News

英國議員投票贊成協助安樂死法案 “`

(SeaPRwire) - 此新聞討論自殺議題。如果您或您認識的人有自殺念頭,請撥打自殺與危機生命線 988 或 1-800-273-TALK (8255)。週五,英國國會下議院通過一項備受爭議的法案,允許患有絕症的成年人結束生命,使英格蘭和威爾斯更接近合法化安樂死。議員以 330 票對 275 票贊成安樂死法案,該法案將送交國會進一步審議,然後才會由議員進行最終表決。擬議的法案將允許 18 歲以上、預期壽命少於六個月的病人請求並獲得協助結束生命,但須符合安全保障和保護措施。在經過數小時的情緒激動的辯論後,此次投票結果出爐,期間分享了個人喪失和痛苦的經歷。這次敏感的討論涉及倫理、悲傷、法律、信仰、犯罪和金錢等問題,辯論期間國會外吸引了大批人群。儘管備受爭議,但根據多項民調顯示,大多數英國人支持安樂死的原則。據歐洲新聞報導,比利時、盧森堡、德國、西班牙、奧地利和葡萄牙等國已將安樂死或協助自殺合法化。瑞士是世界上第一個允許任何形式協助自殺的國家,該行為自 1941 年以來一直合法。美國的 10 個州也已合法化:華盛頓特區和加利福尼亞州、科羅拉多州、俄勒岡州、佛蒙特州、新墨西哥州、緬因州、新澤西州、夏威夷州和華盛頓州。支持者表示,該法律將賦予垂死之人尊嚴,防止不必要的痛苦,同時確保有足夠的保障措施,防止生命垂危者被迫結束自己的生命。反對者,包括宗教領袖,則表示這將使弱勢群體面臨直接或間接被迫結束生命的風險,以免成為別人的負擔。根據提案,兩位醫生和一位高等法院法官需要驗證該人自願做出決定。施壓或脅迫他人結束生命將處以最高 14 年監禁。該法案的主要提案人 Kim Leadbeater 在向擠滿的議會大廳提交法案時表示:「讓我們明確一點,我們談的不是生死攸關的選擇,而是給垂死之人一個選擇死亡方式的權利。」她表示,第二次投票可能需要再六個月。她在週五投票後告訴記者:「我會收集證據,書面證據,口頭證據,我們將組成一個非常徹底、強大的法案委員會來審查法案,並使其盡可能完善。」「這將是一個漫長的過程……然後,正如我在發言中所說,有一段為期兩年的執行期,因此有充足的時間來做好這件事。」還必須考慮如何資助安樂死以及它將如何影響英國的國家資助醫療保健、臨終關懷和法律體系。Danny Kruger 表示,他擔心該法案存在許多漏洞,而且保障措施「並不太強大」。他說:「我們現在還有幾個月的進一步辯論時間,我希望那些表達擔憂的同事們,要不成功地加強法案使其安全,要不他們會得出結論,他們無法做到這一點,然後我們可以在以後的階段,在三讀時否決它。」 贊成該法案。他上個月表示,他「非常高興」看到這樣的投票,並表示他的政府將在這個問題上保持中立,他的議員將獲得自由投票權,而不是必須遵循黨的路線,據 BBC 報導。他內閣的其他成員,包括衛生大臣 Wes Streeting 和司法大臣 Shabana Mahmood,則投了反對票。其他政黨也存在類似的分歧。 Reform UK 的領導人 表示他反對這項措施。Farage 在 X 上寫道:「我反對安樂死法案,不是因為缺乏同情心,而是因為我擔心法律的適用範圍會擴大。」「如果發生這種情況,死的權利可能會變成死的義務。」美聯社和路透社為本報告做出了貢獻。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More

五年後大火,首度一覽修復後的巴黎聖母院內部

(SeaPRwire) - 週五出現的圖片和影片首次展現了巴黎聖母院大教堂在毀滅性大火五年後修復後的內部景象。據路透社報導,在12月8日對外重新開放之前,有人參觀了這座標誌性建築,並形容這次體驗「令人難以置信」。從外部看,這座12世紀的古蹟仍然是一個建築工地,有腳手架和起重機,但在內部,修復工作——包括清除多年累積的污垢——再次展現了大教堂明亮的色彩。「我們非常渴望歡迎全世界來到我們大教堂的屋簷下,」巴黎大主教Laurent Ulrich在其網站上說道,「在2019年4月15日晚上,數十萬人承諾去做當時看似不可能做到的事情:在史無前例的五年期限內修復大教堂並使其恢復昔日的輝煌。」 木匠們像他們中世紀的同行一樣手工操作,他們砍伐巨大的橡木樑來重建在大火中倒塌的屋頂和尖頂。在大火發生後的幾天裡,籌集了近10億美元的捐款。修復主管Philippe Jost表示,其中約有1.48億美元的資金仍然剩餘。他指出,這些資金將「與贊助者和捐贈者協商,用於開展必要的工程」,因為巴黎聖母院仍然面臨著保護和結構完整性的持續需求。 成立於2017年的巴黎聖母院之友非營利組織協助領導了國際籌款工作。巴黎聖母院之友主席Michel Picaud上週告訴Digital,大教堂當時已經處於危險狀態「大火對我們來說是一件可怕的事件,因為我們突然不僅要修復大教堂的一部分,還要重建它,這意味著我們必須做的事情的範圍要大得多。我們非常希望我們能夠成功地重建這座宏偉的建築,」Picaud說道。Macron將於12月7日返回發表講話,並在第二天莊嚴的彌撒中參加新祭壇的祝聖儀式。’ Ashley J. DiMella and 本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
失蹤加拿大遠足客歷經數周酷寒後獲救 News

失蹤加拿大遠足客歷經數周酷寒後獲救

(SeaPRwire) - 根據皇家加拿大騎警隊 (RCMP) 的說法,一名失蹤超過六個星期的遠足者在本周較早時間被找到。北方落磯山脈皇家加拿大騎警隊 (Northern Rockies RCMP) 於星期二上午 11 時 30 分左右接到通知,指 20 歲的 Sam Benastick 已被找到。他的家人於 10 月 19 日報案指他失蹤。Benastick 的家人在他於 10 月 7 日開始為期 10 天的遠足後沒有按時聯絡時,開始感到擔憂。當時正值嚴酷的冬季條件,氣溫驟降至華氏 4 度以下。Benastick 是被兩名前往 Redfern Lake Trail 工作的人發現的,當時他正朝他們走來。他使用登山杖支撐自己,並用撕開的睡袋保暖腿部。這兩名男子將 Benastick 送往醫院,警方證實他就是失蹤的露營者。他告訴警方,他曾有一段時間待在車裡,然後步行到一個地點,在那裡露營了 10 到 15 天。之後,他沿著山谷向下移動,在乾涸的河床上搭建了一個營地和住所,最後才向這兩名男子求救。「找到 Sam 還活著,這是最好的結果。在他失蹤這麼長時間後,人們擔心這不會是結果,」皇家加拿大騎警隊 (RCMP) 警官 Madonna Saunderson 說。該機構接著感謝在搜救行動中提供互助支援的眾多司法管轄區,以及擁有該地區廣泛內陸知識的加拿大遊騎兵和志願者。「從接到他失蹤的通知開始,為尋找 Sam 所投入的時間、精力和資源是無法估量的。我們感謝這個美好的結果,」Saunderson 說。他的姐姐在他失蹤後設立了一個 GoFundMe 頁面,用於協助支付尋找他的費用。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Paratus公司將返還資本的相關重要資訊 Business

Paratus公司將返還資本的相關重要資訊

(SeaPRwire) - 百慕達,哈密爾頓,2024年11月29日 — Paratus Energy Services Ltd. (OSL: PLSV)(「Paratus」或「公司」)今日宣佈,董事會已批准向股東發放現金分派,詳情如下。該分派將以資本回報的形式進行,並將來自公司已繳入盈餘賬戶,該賬戶包含從公司股本溢價賬戶轉移的先前已繳入的股本溢價。 以下是關於資本回報的關鍵資訊: 資本回報:每股0.22美元 宣佈貨幣:美元 最後計入權利日:2024年12月2日 除息日:2024年12月3日 記錄日:2024年12月4日 付款日:2024年12月13日 批准日期:2024年11月28日 現金分派以美元宣佈,每股實際挪威克朗支付金額將根據換算時的適用匯率確定,該匯率將盡可能在支付日期之前設定。對於持有歐元區證券交易所奧斯陸/VPS以外股份的股東,現金分派的支付將以人工方式處理。 根據挪威證券交易法第5-12條的披露要求,提供此資訊。 如需了解更多資訊,請聯繫: Baton Haxhimehmedi,財務總監,+47 406 39 083 關於Paratus Paratus Energy Services Ltd. (股票代碼:PLSV) 是一家投資控股公司,旗下擁有一批領先的能源服務公司。Paratus集團主要包括其對Fontis Energy的擁有權以及在Seagems(前稱Seabras)中50/50的合資企業權益。Fontis Energy 是一家離岸鑽探公司,擁有五艘高規格自升式鑽井平台,根據在墨西哥的合約運作。Seagems 是一家領先的海底服務公司,擁有六艘多用途管道鋪設支援船,根據在巴西的合約運作。此外,Paratus 是Archer Ltd 的最大股東,Archer Ltd 是一家在歐元區奧斯陸證券交易所上市的全球石油服務公司。 此資訊由Cision提供本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
媒體公告-加拿大政府將在海河宣布住房計劃 Business

媒體公告-加拿大政府將在海河宣布住房計劃

(SeaPRwire) - 加拿大西北地區海河鎮, 2024年11月28日 – 媒體受邀加入麥克勞德議員(Michael McLeod),加拿大西北地區國會議員——代表加拿大住房、基礎設施和社區部長肖恩·弗雷澤(Sean Fraser)閣下——以及西北地區首長R.J 辛普森(Simpson),一同參與一項重要的房屋政策宣佈。 日期: 2024年11月29日 時間: 上午11:30 山區時間 地點: 加拿大西北地區海河鎮66號首都大道,X0E 0R0 資料來源 加拿大政府 (Government of Canada)本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Beard Bros Media 報導拜登總統「赦免」火雞,同時數百名聯邦囚犯如艾德溫·魯比斯因非暴力大麻罪行 languish 數十年 Business

Beard Bros Media 報導拜登總統「赦免」火雞,同時數百名聯邦囚犯如艾德溫·魯比斯因非暴力大麻罪行 languish 數十年

(SeaPRwire) - 洛杉磯, 2024年11月28日 — “他們告訴我,這裡有2500人在尋求赦免,”總統喬·拜登週一在白宮對人群說道。這些話並沒有在任何實際的特赦請求被批准之前宣布。相反,它們是在總統“赦免”兩隻火雞之前開玩笑說的,諷刺的是他們將被囚禁的地方。 拜登總統繼續赦免火雞,而不是囚犯。為那些無法為自己發聲的人發聲。 在11月20日,60名國會議員簽署並遞交給拜登總統,懇求他利用賦予他職位的獨特特赦權。“今天服刑多年的許多人之所以在那裡,是因為他們犯下的罪行是無受害者的。這令人震驚,應該得到解決,”眾議員吉姆·克萊伯恩(南卡羅來納州民主黨)在美國國會山舉行的新聞發佈會上說。 拜登總統回覆了火雞,而不是他國會中的長期盟友,“根據你們的性情和你們對成為社會有益成員的承諾,我特此赦免桃子和布洛森。” 埃德溫·魯比斯根據1990年代末期非暴力大麻販運指控,已服刑27年,刑期為40年。魯比斯有良好行為記錄,在獄中獲得了三個大學學位,並完成了30多個康復計劃。他期待一旦獲釋後從事諮詢工作。 埃德溫·魯比斯和數百名像他一樣的人正在尋求減刑。致力於成為社會有益成員的人。是時候拜登總統認真對待人權和大規模監禁問題了。是時候釋放埃德溫·魯比斯了。 了解更多信息,請訪問或聯繫: 您可以閱讀完整的新聞稿 您可以直接向此項事業捐款 關於Freedom GrowFreedom Grow 是一個全志願者非營利性 501c3 組織,幫助大麻囚犯重獲自由,同時通過“願望計劃”支持他們的犧牲。“願望計劃”幫助囚犯獲得伙食費、書籍、雜誌、家庭聯繫和公眾教育。 這篇新聞文章包含比爾·利弗斯的觀點,雖然是主觀的,但故事的事實並不打算對被定罪的個人或本文中的法律事項和事實呈現虛假或誤導性信息。 資料來源 Beard Bros Media本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
與Jason一起暢遊中國國際供應鏈博覽會:供應鏈如何推動未來製造業 Business

與Jason一起暢遊中國國際供應鏈博覽會:供應鏈如何推動未來製造業

(SeaPRwire) - 北京, 2024年11月29日 — 這是來自中國國新網的報導: 第二屆中國國際供應鏈博覽會已開幕,Jason回來了!Jason帶您參觀未來感十足的先進製造區: 可愛的吉祥物Linky是如何誕生於神秘的「魔法盒」中?Jason在京冶集團的展位找到了答案,在那裡他了解到金屬3D列印技術。該技術利用雷射技術熔化金屬粉末,可以列印出幾乎任何形狀的複雜、精密的零件,從而降低成本並提高效率。 在這個區域,Jason還了解到寶鋼集團開發的一種新型材料——稀土鋼,以及康寧公司熔融工藝生產的玻璃。 這些材料的開發代表了製造業的上游流程。下一階段是組件加工,其中外國公司大量參與。 日本的住友電氣,例如,正在展示其汽車零部件和海底電纜的供應鏈。機器人調酒師使用西門子的Workflow Canvas,通過面部表情和語氣分析顧客的情緒,推薦並調製個性化飲品。然後是克諾爾-布雷姆斯,一家以其制動系統聞名的德國「隱形冠軍」。 憑藉這些先進技術和關鍵組件,我們現在可以生產複雜的設備,包括國家基礎設施項目中使用的關鍵機械。Jason了解到雲河隧道掘進機和上海洋山港的自動化碼頭項目。 從設計和研發到關鍵國家設備的加工和智能製造,您可以看到一條連接上游、中游和下游公司,聯繫各國並引領未來的先進製造供應鏈。 Tag along with Jason at CISCE: How supply chains drive futuristic manufacturing 資料來源 China SCIO本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
AEON 推出授權支付,透過 TON 轉變日常交易
“` Business

AEON 推出授權支付,透過 TON 轉變日常交易 “`

(SeaPRwire) - 新加坡, 2024年11月29日 — AEON,一個領先的支付協議,自豪地宣佈其最新創新:一個基於TON區塊鏈的革命性授權支付功能。通過為TON生態系統的基礎設施貢獻力量,AEON增強了區塊鏈技術在日常場景中的可用性。這一創新的第一個實際應用是在ShareX的Telegram小程序中,AEON簡化了行動電源的租賃流程,展示了區塊鏈變革日常交易的潛力。 AEON革新TON上的支付 AEON基於TON區塊鏈的授權支付,通過簡化和安全的用戶流程徹底改變了交易流程。用戶首先選擇所需的服務或產品並啟動交易。AEON的系統會提示他們授權支付,安全地鎖定所需金額。完成後,用戶可以無縫訪問服務或產品,無需額外的支付步驟。服務或交易完成後,支付將根據初始授權自動處理,確保平穩安全的結算,無需人工干預。 將AEON整合到TON生態系統中,通過簡化支付流程、減少拒付並增強交易的整體安全性,為用戶帶來無與倫比的便利。通過利用TON區塊鏈強大的基礎設施,AEON支持各種加密貨幣和錢包整合,使用戶可以輕鬆選擇其首選的支付方式。這一發展進一步鞏固了TON生態系統在安全、透明和可靠性方面的聲譽,使加密貨幣支付更易於訪問和使用。 第一個用例:ShareX的行動電源Telegram小程序 在第一個實際應用中,AEON的授權支付解決方案已整合到ShareX的Telegram小程序中。這簡化了租賃流程,允許用戶通過TON生態系統中的AEON支付協議預先授權押金。授權金額預先安全鎖定,使用戶可以立即訪問服務。租賃完成後,將根據預授權自動處理付款,扣除費用並解鎖餘額。此無縫流程減少了人工步驟,最大限度地降低了用戶和供應商的風險,並增強了信任,展示了基於區塊鏈的支付在日常場景中的效率。 展望未來 這一里程碑體現了AEON致力於推進TON的生態系統基礎設施並促進區塊鏈在日常交易中的普及。隨著AEON繼續在TON領域創新,未來的擴展將為各個行業帶來多樣化的支付應用。通過這些努力,AEON旨在推動加密貨幣支付的採用,賦能TON生態系統,並為全球消費者、商家和行業提供變革性的解決方案。通過建立在TON的基礎之上,AEON正在塑造一個更加互聯互通和高效的Web3金融生態系統,重新定義加密貨幣支付格局。 關於TON 開放網絡 (TON) 是一個全球性的去中心化區塊鏈社區,致力於將加密貨幣普及到每個人的手中。通過在Telegram Messenger中構建Web3生態系統,TON的願景是讓5億用戶在2028年前擁有自己的數字身份、數據和資產。了解更多信息,請訪問 關於AEON AEON是一個新一代的模塊化支付協議,旨在統一加密貨幣支付的標準並實現與現實世界的連接。通過簡化加密貨幣支付的整合、處理和結算,AEON提供低成本、可驗證和安全的支付處理。 AEON致力於開發一個強大的加密貨幣支付標準,旨在將web3基礎設施與大規模採用的用例相連接,確保適應性、流動性和效率,並支持基於區塊鏈的支付方法,例如訂閱、全球法幣通道和小費。 資料來源 AEON本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Acme, Founder of ACET, Calling on Thailand’s Embrace of Digital Assets SeaPRwire

Acme, Founder of ACET, Calling on Thailand’s Embrace of Digital Assets

London, United Kingdom – November 30, 2024 – (SeaPRwire) – Recently, ACET celebrated reaching 150,000 holders worldwide. ACET founder Worawat “Acme” Narknawdee the 36-year old visionary Billionnaire, financial innovator, investor, and entrepreneur is calling on the Thai government to embrace Bitcoin as part of its international reserve fund. The Possibility of Bitcoin as Thailand’s Reserve Fund Acme believes that Bitcoin is no longer just a digital currency, but a force poised to transform the global economy. With Bitcoin’s market value surging to unprecedented heights, Acme argues that now is the time for Thailand to position itself as a leader in the digital age. Acme envisions Bitcoin as an indispensable asset that can help Thailand diversify its financial reserves, improve economic stability, and lead the way in blockchain innovation. While the volatility and regulatory concerns surrounding Bitcoin are valid, Acme believes these obstacles are surmountable with proper education, infrastructure, and regulatory reform. “Thailand stands at a crossroads,” Acme explained. “The future of money is digital, and Bitcoin is the key to unlocking the potential of a fully digital economy. By taking bold steps today, Thailand can lead the region and set the stage for long-term prosperity in the global digital economy.” “Bitcoin is more than a currency,” said Acme. “It is a revolutionary technology that can drive the future of finance, and Thailand has the potential to lead this charge.” His proposal is to integrate Bitcoin into Thailand’s reserves to enhance economic diversification, improve resilience against global volatility, and ultimately fuel the country’s digital economy. This strategic move could place Thailand at the forefront of blockchain technology and digital currency adoption in Southeast Asia. The Bold Path Forward Acme’s proposal may seem daring, but it offers an opportunity for Thailand to embrace the future, tapping into the transformative power of Bitcoin and blockchain technology. As the world increasingly moves toward a digital-first economy, Thailand’s decision to integrate Bitcoin into its reserves could serve as a catalyst for long-term growth and innovation, attracting global investment and positioning the nation as a true leader in the digital era. About Acme, Founder of ACET Since 2012, Acme has not only been an avid investor but also the largest Bitcoin holder in Thailand. While the exact number of BItcoins owned by Mr. Worawat has not yet been disclosed, sources from the crypto community estimated he was holding at least 11,000 BTC, more thn twice the amount of Bitcoins held by the Government of El Salvador, which declared Bitcoin as a legal tender in 2021. His commitment to the cryptocurrency ecosystem has shaped him into a thought leader in the space. In 2021, Acme solidified his place in the global fintech arena by launching ACT (ACET), a cryptocurrency coin that now boasts over 150,000 holders worldwide, with a total market value of more than $300 million USD. Acme’s influence extends beyond business. Known for his philanthropy, he has held two record-breaking Bitcoin giveaways, in 2017 and 2021, where he gifted a combined total of 16 Bitcoins (worth over 1.5 million USD at today’s prices) to fans, promoting cryptocurrency education and awareness. His commitment to sharing knowledge and empowering others has made him a household name in Thailand’s crypto community and beyond. Social Links X: https://x.com/ACTDeFansFi Facebook: https://www.facebook.com/ACTDeFansFi/ Telegram: https://t.me/ACTAcet Github: https://acet-finance.gitbook.io/act Media contact Brand: ACET Contact: Corporate Communication Division Email: media@acet.finance Website: https://acet.finance/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

NEFECON(R) Included in National Reimbursement Drug List (NRDL)

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the "National Reimbursement Drug List (2024)" (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. This milestone signifies a breakthrough in advancing the standardization of IgAN treatment and improving accessibility and affordability, offering hope for millions of IgAN patients in China. NEFECON(R) has been prescribed in mainland China since May this year and has been approved in Macau, Hong Kong, Taiwan, China, South Korea and in Singapore under the trade name Nefegan(R).NEFECON(R) is the first ever treatment for IgAN to receive full approval from the U.S. Food and Drug Administration (FDA) and the first non-oncology therapeutic to receive breakthrough therapy designation in China by the China National Medical Products Administration (NMPA), underscoring its globally leading position and exceptional clinical value. Recently, at the 2024 American Society of Nephrology (ASN) Annual Meeting, data from the open-label extension (OLE) phase of the NefIgArd Phase 3 trial demonstrated that patients undergoing a second course of NEFECON(R) treatment experienced similar benefits in estimated glomerular filtration rate (eGFR) preservation and proteinuria reduction as observed after the initial treatment, with good tolerance. These findings further validate the feasibility and efficacy of long-term treatment strategies, aligning with recommendations from the "KDIGO 2024 Clinical Practice Guideline for The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV)", highlighting NEFECON(R)'s innovation and clinical value in IgAN treatment. NEFECON(R) was also listed as the only treatment proven to reduce the levels of pathogenic forms of IgA and IgA immune complexes.IgAN is highly prevalent in Asia and is one of the main causes of kidney failure in young adults in China. Statistics show that with approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand. Since NEFECON(R)'s first prescription was issued in Mainland China in May 2024, the product has demonstrated strong market performance. According to Everest Medicines' interim report, NEFECON(R) achieved RMB1.673 billion in sales within its first month, reflecting widespread recognition of its therapeutic benefits and the significant demand for innovative therapies among Chinese patients.With NEFECON(R)'s successful inclusion in the NRDL, its accessibility and coverage in China are expected to increase significantly, driving sustained and robust commercial revenue growth for Everest Medicines. This milestone not only strengthens the company's leadership in nephrology but also injects new momentum into optimizing resource allocation and promoting synergistic development. As reimbursement coverage leads to expanded market penetration, this development is poised to be a key catalyst in unlocking the full value of the company's core products, further accelerating the reevaluation of its market potential.NEFECON(R) included in the NRDL is a testament to Everest Medicines' differentiated commercial strategy. Another core product, XERAVA(R) (eravacycline) is the world's first fluorocycline antibiotic for the treatment of complicated intra-abdominal infections, continues to excel in the field of complicated intra-abdominal infections. According to the recently released final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", the drug demonstrated an impressive overall treatment effectiveness rate of 90.1%, further affirming its clinical value and safety. As of the first half of 2024, XERAVA(R) achieved cumulative sales of RMB2.33 billion, underscoring its strong market acceptance and potential.In the autoimmune disease portfolio, VELSIPITY(R) continues to make steady progress in its commercialization journey. In October, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) received approval from the Guangdong Provincial Medical Products Administration and is now available for use in three designated medical institutions within the Greater Bay Area. Earlier this year, VELSIPITY(R) was also approved for use in Macau and Singapore. In addition, Everest Medicines recently submitted a new drug application (NDA) for VELSIPITY(R) in Hong Kong and plans to submit an NDA in Mainland China by the end of the year. As Everest Medicines' third commercialized product, VELSIPITY(R) is poised to become a key growth driver, with significant market potential expected to unfold as its adoption expands further.Everest Medicines continues to make significant strides in innovative R&D, with its proprietary mRNA development platform now fully localized. The company's first personalized mRNA cancer vaccine, EVM16, has Initiated an Investigator-Initiated Clinical Trial (IIT). Additionally, EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor being developed globally for the treatment of renal diseases, marks another important advancement. Everest Medicines will host an investor call on December 4th to discuss the results of the Phase 1b/2a clinical study of EVER001 in primary membranous nephropathy, highlighting its potential to drive future growth.Driven by the inclusion of NEFECON(R) in the NRDL and the continued progress of its core pipeline, Everest Medicines' business model demonstrates its resilience and strength. The company remains steadfast in fulfilling its commitments to investors while strengthening market confidence in its innovation and long-term growth potential. With a diversified focus on renal, infectious, and autoimmune diseases, Everest Medicines is harnessing its robust commercialization platform to fuel growth, steadily advancing toward its vision of becoming Asia's leading global biopharmaceutical company. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

NEFECON(R) Included in National Reimbursement Drug List (NRDL)

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the "National Reimbursement Drug List (2024)" (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. This milestone signifies a breakthrough in advancing the standardization of IgAN treatment and improving accessibility and affordability, offering hope for millions of IgAN patients in China. NEFECON(R) has been prescribed in mainland China since May this year and has been approved in Macau, Hong Kong, Taiwan, China, South Korea and in Singapore under the trade name Nefegan(R).NEFECON(R) is the first ever treatment for IgAN to receive full approval from the U.S. Food and Drug Administration (FDA) and the first non-oncology therapeutic to receive breakthrough therapy designation in China by the China National Medical Products Administration (NMPA), underscoring its globally leading position and exceptional clinical value. Recently, at the 2024 American Society of Nephrology (ASN) Annual Meeting, data from the open-label extension (OLE) phase of the NefIgArd Phase 3 trial demonstrated that patients undergoing a second course of NEFECON(R) treatment experienced similar benefits in estimated glomerular filtration rate (eGFR) preservation and proteinuria reduction as observed after the initial treatment, with good tolerance. These findings further validate the feasibility and efficacy of long-term treatment strategies, aligning with recommendations from the "KDIGO 2024 Clinical Practice Guideline for The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV)", highlighting NEFECON(R)'s innovation and clinical value in IgAN treatment. NEFECON(R) was also listed as the only treatment proven to reduce the levels of pathogenic forms of IgA and IgA immune complexes.IgAN is highly prevalent in Asia and is one of the main causes of kidney failure in young adults in China. Statistics show that with approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand. Since NEFECON(R)'s first prescription was issued in Mainland China in May 2024, the product has demonstrated strong market performance. According to Everest Medicines' interim report, NEFECON(R) achieved RMB1.673 billion in sales within its first month, reflecting widespread recognition of its therapeutic benefits and the significant demand for innovative therapies among Chinese patients.With NEFECON(R)'s successful inclusion in the NRDL, its accessibility and coverage in China are expected to increase significantly, driving sustained and robust commercial revenue growth for Everest Medicines. This milestone not only strengthens the company's leadership in nephrology but also injects new momentum into optimizing resource allocation and promoting synergistic development. As reimbursement coverage leads to expanded market penetration, this development is poised to be a key catalyst in unlocking the full value of the company's core products, further accelerating the reevaluation of its market potential.NEFECON(R) included in the NRDL is a testament to Everest Medicines' differentiated commercial strategy. Another core product, XERAVA(R) (eravacycline) is the world's first fluorocycline antibiotic for the treatment of complicated intra-abdominal infections, continues to excel in the field of complicated intra-abdominal infections. According to the recently released final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", the drug demonstrated an impressive overall treatment effectiveness rate of 90.1%, further affirming its clinical value and safety. As of the first half of 2024, XERAVA(R) achieved cumulative sales of RMB2.33 billion, underscoring its strong market acceptance and potential.In the autoimmune disease portfolio, VELSIPITY(R) continues to make steady progress in its commercialization journey. In October, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) received approval from the Guangdong Provincial Medical Products Administration and is now available for use in three designated medical institutions within the Greater Bay Area. Earlier this year, VELSIPITY(R) was also approved for use in Macau and Singapore. In addition, Everest Medicines recently submitted a new drug application (NDA) for VELSIPITY(R) in Hong Kong and plans to submit an NDA in Mainland China by the end of the year. As Everest Medicines' third commercialized product, VELSIPITY(R) is poised to become a key growth driver, with significant market potential expected to unfold as its adoption expands further.Everest Medicines continues to make significant strides in innovative R&D, with its proprietary mRNA development platform now fully localized. The company's first personalized mRNA cancer vaccine, EVM16, has Initiated an Investigator-Initiated Clinical Trial (IIT). Additionally, EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor being developed globally for the treatment of renal diseases, marks another important advancement. Everest Medicines will host an investor call on December 4th to discuss the results of the Phase 1b/2a clinical study of EVER001 in primary membranous nephropathy, highlighting its potential to drive future growth.Driven by the inclusion of NEFECON(R) in the NRDL and the continued progress of its core pipeline, Everest Medicines' business model demonstrates its resilience and strength. The company remains steadfast in fulfilling its commitments to investors while strengthening market confidence in its innovation and long-term growth potential. With a diversified focus on renal, infectious, and autoimmune diseases, Everest Medicines is harnessing its robust commercialization platform to fuel growth, steadily advancing toward its vision of becoming Asia's leading global biopharmaceutical company. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap ACN Newswire

Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap

SAN FRANCISCO, CA & MUMBAI, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Niyo, India’s leading fintech startup, teamed up with CleverTap, the all-in-one engagement platform, to improve customer experiences through personalized engagement and real-time interactions. Since its founding in 2015, Niyo has been revolutionizing financial services in India, particularly with its international travel cards and app-based financial services, catering to the evolving needs of its users.In its almost decade-long journey, Niyo recognized the challenges that modern Indian travellers face at every touchpoint while venturing abroad. It sought a feature-rich user engagement platform that would effectively deliver the right solutions to its customers and found the ideal partner in CleverTap. By leveraging CleverTap’s advanced automation tools, Niyo enhanced its onboarding processes, while ensuring compliance with regulations, and streamlining customer experiences. This collaboration empowered Niyo to reduce drop-offs during the customer journey, automate personalized messages, and re-engage dormant users.By deploying CleverTap’s integrated platform, Niyo achieved:・2x increase in click through rates, leveraging Clever.AI for emotionally intelligent content.・40% optimized conversion rate through pinpoint targeting, ensuring personalized and relevant communication at every step.・12% re-engagement of dormant users through targeted campaigns, highlighting Niyo’s success in winning back inactive customers.Sushanth Ravikumar, SVP - Head of Marketing, Niyo, said - “At Niyo, delivering a seamless and personalized experience for our customers is a top priority. CleverTap has been instrumental in elevating this experience. Its robust automation and communication tools have streamlined our onboarding process while maintaining compliance in the highly regulated sector. What started as a tool to streamline everyday operations has become a key force in helping us preserve customer trust, even during challenging times. Its ability to adapt to real-time shifts in customer engagement offers us a definitive edge in an ever-changing dynamic, solidifying our long-term confidence in the platform.”Sidharth Pisharoti, Chief Revenue Officer, CleverTap, said - “We are excited to collaborate with Niyo as they continue to innovate in the travel fintech space. Through our partnership, we’ve been able to enhance Niyo’s customer engagement by focusing on delivering personalized and timely experiences. This has not only streamlined their processes but also improved customer satisfaction, particularly in key areas like onboarding and transaction management. We look forward to supporting Niyo as they scale and evolve their offerings in this dynamic market.”About Niyo Niyo is India’s leading banking fintech that has revolutionized "travel banking" for Indians. The company was co-founded by banking veteran Vinay Bagri (currently, CEO) and technology veteran Virender Bisht (currently, CTO) in 2015. Niyo offers zero forex debit and credit cards, which provides the best banking experience and value for international travellers. This unique solution was invented by Niyo in 2015 and has helped over 2 million Indians by saving more up to 5% on their international transactions with Zero Forex offering. In this last Series-C round in 2022, Niyo raised $130 million, which was led by global VC and PE firms, Accel, Lightrock, and Multiples. Its other investors include Prime Venture Partners, Horizons Ventures, Tencent, JS Capital, Social Capital, and Beams Fintech Fund. Niyo operates out of a corporate office in Bengaluru and has a sales presence in more than 20 states and union territories.Visit: GoNiyo.comAbout CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco, to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit CleverTap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications and CSR, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap ACN Newswire

Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap

SAN FRANCISCO, CA & MUMBAI, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Niyo, India’s leading fintech startup, teamed up with CleverTap, the all-in-one engagement platform, to improve customer experiences through personalized engagement and real-time interactions. Since its founding in 2015, Niyo has been revolutionizing financial services in India, particularly with its international travel cards and app-based financial services, catering to the evolving needs of its users.In its almost decade-long journey, Niyo recognized the challenges that modern Indian travellers face at every touchpoint while venturing abroad. It sought a feature-rich user engagement platform that would effectively deliver the right solutions to its customers and found the ideal partner in CleverTap. By leveraging CleverTap’s advanced automation tools, Niyo enhanced its onboarding processes, while ensuring compliance with regulations, and streamlining customer experiences. This collaboration empowered Niyo to reduce drop-offs during the customer journey, automate personalized messages, and re-engage dormant users.By deploying CleverTap’s integrated platform, Niyo achieved:・2x increase in click through rates, leveraging Clever.AI for emotionally intelligent content.・40% optimized conversion rate through pinpoint targeting, ensuring personalized and relevant communication at every step.・12% re-engagement of dormant users through targeted campaigns, highlighting Niyo’s success in winning back inactive customers.Sushanth Ravikumar, SVP - Head of Marketing, Niyo, said - “At Niyo, delivering a seamless and personalized experience for our customers is a top priority. CleverTap has been instrumental in elevating this experience. Its robust automation and communication tools have streamlined our onboarding process while maintaining compliance in the highly regulated sector. What started as a tool to streamline everyday operations has become a key force in helping us preserve customer trust, even during challenging times. Its ability to adapt to real-time shifts in customer engagement offers us a definitive edge in an ever-changing dynamic, solidifying our long-term confidence in the platform.”Sidharth Pisharoti, Chief Revenue Officer, CleverTap, said - “We are excited to collaborate with Niyo as they continue to innovate in the travel fintech space. Through our partnership, we’ve been able to enhance Niyo’s customer engagement by focusing on delivering personalized and timely experiences. This has not only streamlined their processes but also improved customer satisfaction, particularly in key areas like onboarding and transaction management. We look forward to supporting Niyo as they scale and evolve their offerings in this dynamic market.”About Niyo Niyo is India’s leading banking fintech that has revolutionized "travel banking" for Indians. The company was co-founded by banking veteran Vinay Bagri (currently, CEO) and technology veteran Virender Bisht (currently, CTO) in 2015. Niyo offers zero forex debit and credit cards, which provides the best banking experience and value for international travellers. This unique solution was invented by Niyo in 2015 and has helped over 2 million Indians by saving more up to 5% on their international transactions with Zero Forex offering. In this last Series-C round in 2022, Niyo raised $130 million, which was led by global VC and PE firms, Accel, Lightrock, and Multiples. Its other investors include Prime Venture Partners, Horizons Ventures, Tencent, JS Capital, Social Capital, and Beams Fintech Fund. Niyo operates out of a corporate office in Bengaluru and has a sales presence in more than 20 states and union territories.Visit: GoNiyo.comAbout CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco, to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit CleverTap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications and CSR, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange ACN Newswire

Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - China’s largest retail digitalization solution provider – Dmall Inc. (“Dmall” or the “Company”, Stock Code: 02586.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”).Dmall plans to offer 25,774,000 Shares (subject to the over-allotment option), of which 23,196,600 Shares will be International Offer Shares (subject to reallocation and the over-allotment option), representing approximately 90% of the initial offer shares; the remaining 2,577,400 Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$30.21 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Dmall will open for Hong Kong Public Offering in Hong Kong at 9 a.m., November 28, 2024 (Thursday), and close at 11:30 a.m., December 3, 2024 (Tuesday). Dealings in shares of Dmall on the Main Board of the Hong Kong Stock Exchange is expected to commence on December 6, 2024 (Friday). The shares will be traded in board lot of 100 shares each. The Company’s stock code will be 02586.HK.UBS Securities Hong Kong Limited, CMB International Capital Limited and China Merchants Securities (HK) Co., Limited are the Joint Sponsors. UBS AG Hong Kong Branch, CMB International Capital Limited, China Merchants Securities (HK) Co., Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators, Overall Coordinators, Joint Bookrunners and Joint Lead Managers.After deducting the underwriting commissions and other estimated offering expenses payable by the Company, with an Offer Price of HK$30.21 per Offer Share, the Company estimates that it will receive net proceeds of approximately HK$623.7 million from the Global Offering after deducting the underwriting commissions and fees, and other estimated expenses in connection with the Global Offering and assuming that the Over-allotment Option is not exercised. In line with Dmall’s strategies, the proceeds from the Global Offering are intended to be used for the following purposes and in the following amounts – approximately 42.1%, or HK$262.6 million, to develop new applications and new service modules; approximately 30.0%, or HK$187.1 million, for talent acquisition associated with the expansion of Dmall’s operations; approximately 10.0%, or HK$62.4 million, to selectively pursue strategic cooperation, investments and acquisitions that are complementary to its organic growth strategies, particularly those that can complement Dmall’s product offerings, strengthen its technology capabilities, and solidify its market position; approximately 7.9%, or HK$49.3 million, to expand its sales network and further strengthen its brand reputation; and approximately 10.0%, or HK$62.4 million, for working capital and general corporate purposes.Dmall was founded in 2015, which provides retail digitalization solutions to retailers in the local retail industry. According to Frost & Sullivan, Dmall is the largest retail cloud solution provider in China by GMV, with a market share of 13.3% in 2023. The expansion has allowed the Company to become the largest retail cloud solution provider in Asia by GMV in 2023, occupied a market share of 10.9%, according to Frost & Sullivan.As a leading retail digitalization solution provider in Asia, the broadest operational modules coverage enables Dmall to cover diverse customer base in the retail industry and thus obtain deep retail know-how, meet the needs of all major aspects of the retailer's operations. Dmall served 444 customers in the six months ended June 30, 2024, such as Pangdonglai, Luosen (China), Dennis and Maidelong Entities, as well as well-known brands such as Wellcome, Mannings, Guardian, Giant and 7-Eleven (Hong Kong), which operate under the DFI Retail Group, demonstrating a widely validated operating model. The dollar-based net retention ratio was 184% in 2021, 158% in 2022, 117% in 2023 and 123% in the twelve months ended June 30, 2024, remaining robust at above 100%, which underscores Dmall’s ability to further increase customer spending.Dmall has always attached importance to the value created for customers, “customer success” is the starting point of everything the Company does. Dmall has provided services to leading companies in different retail formats, and has successfully expanded its businesses markets outside of the Chinese mainland, comprising Hong Kong SAR, Cambodia, Singapore, Malaysia, Poland, Macau SAR, Indonesia, the Philippines and Brunei. In terms of income, the overseas income of the Company in 2023 has exceeded RMB100 million.Dmall achieved strong revenue growth as its revenue grew by 56.6% from RMB848.2 million in 2021 to RMB1,328.3 million in 2022, and further increased by 19.4% to RMB1,585.4 million in 2023. Dmall’s revenue increased by 22.9% from RMB764.0 million in the six months ended June 30, 2023 to RMB939.2 million in the six months ended June 30, 2024. Dmall has also improved its gross margin during the Track Record Period. Dmall’s gross margins were 20.4%, 38.0%, 35.0%, 36.3% and 38.3% in the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.Mr. Zhang Feng, co-founder, executive Director and president of Dmall said, “We empower retailers to thrive in the digital era and are committed to becoming the world's leading omnichannel retail digital solutions provider. We will uphold the values of "continuous innovation", always strive, constantly strengthen and uphold our own technical barriers and optimize products and services, maintain core competitiveness, continue to provide customers with high-value services, and help customers' business. We look forward to taking the listing as an opportunity to fully leverage our competitive advantages and utilize Hong Kong's unique financing platform to further enhance our strengths and continue to create greater value for our shareholders and investors.”Issued by Porda Havas International Finance Communications Group for and on behalf of Dmall Inc. For further information, please contact:Porda Havas International Finance Communications GroupMS.Fung Kelly(852) 3150 6763kelly.fung@h-advisors.globalMS.Wang Evie(86) 135 2006 8960evie.wang@h-advisors.global Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange ACN Newswire

Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - China’s largest retail digitalization solution provider – Dmall Inc. (“Dmall” or the “Company”, Stock Code: 02586.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”).Dmall plans to offer 25,774,000 Shares (subject to the over-allotment option), of which 23,196,600 Shares will be International Offer Shares (subject to reallocation and the over-allotment option), representing approximately 90% of the initial offer shares; the remaining 2,577,400 Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$30.21 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Dmall will open for Hong Kong Public Offering in Hong Kong at 9 a.m., November 28, 2024 (Thursday), and close at 11:30 a.m., December 3, 2024 (Tuesday). Dealings in shares of Dmall on the Main Board of the Hong Kong Stock Exchange is expected to commence on December 6, 2024 (Friday). The shares will be traded in board lot of 100 shares each. The Company’s stock code will be 02586.HK.UBS Securities Hong Kong Limited, CMB International Capital Limited and China Merchants Securities (HK) Co., Limited are the Joint Sponsors. UBS AG Hong Kong Branch, CMB International Capital Limited, China Merchants Securities (HK) Co., Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators, Overall Coordinators, Joint Bookrunners and Joint Lead Managers.After deducting the underwriting commissions and other estimated offering expenses payable by the Company, with an Offer Price of HK$30.21 per Offer Share, the Company estimates that it will receive net proceeds of approximately HK$623.7 million from the Global Offering after deducting the underwriting commissions and fees, and other estimated expenses in connection with the Global Offering and assuming that the Over-allotment Option is not exercised. In line with Dmall’s strategies, the proceeds from the Global Offering are intended to be used for the following purposes and in the following amounts – approximately 42.1%, or HK$262.6 million, to develop new applications and new service modules; approximately 30.0%, or HK$187.1 million, for talent acquisition associated with the expansion of Dmall’s operations; approximately 10.0%, or HK$62.4 million, to selectively pursue strategic cooperation, investments and acquisitions that are complementary to its organic growth strategies, particularly those that can complement Dmall’s product offerings, strengthen its technology capabilities, and solidify its market position; approximately 7.9%, or HK$49.3 million, to expand its sales network and further strengthen its brand reputation; and approximately 10.0%, or HK$62.4 million, for working capital and general corporate purposes.Dmall was founded in 2015, which provides retail digitalization solutions to retailers in the local retail industry. According to Frost & Sullivan, Dmall is the largest retail cloud solution provider in China by GMV, with a market share of 13.3% in 2023. The expansion has allowed the Company to become the largest retail cloud solution provider in Asia by GMV in 2023, occupied a market share of 10.9%, according to Frost & Sullivan.As a leading retail digitalization solution provider in Asia, the broadest operational modules coverage enables Dmall to cover diverse customer base in the retail industry and thus obtain deep retail know-how, meet the needs of all major aspects of the retailer's operations. Dmall served 444 customers in the six months ended June 30, 2024, such as Pangdonglai, Luosen (China), Dennis and Maidelong Entities, as well as well-known brands such as Wellcome, Mannings, Guardian, Giant and 7-Eleven (Hong Kong), which operate under the DFI Retail Group, demonstrating a widely validated operating model. The dollar-based net retention ratio was 184% in 2021, 158% in 2022, 117% in 2023 and 123% in the twelve months ended June 30, 2024, remaining robust at above 100%, which underscores Dmall’s ability to further increase customer spending.Dmall has always attached importance to the value created for customers, “customer success” is the starting point of everything the Company does. Dmall has provided services to leading companies in different retail formats, and has successfully expanded its businesses markets outside of the Chinese mainland, comprising Hong Kong SAR, Cambodia, Singapore, Malaysia, Poland, Macau SAR, Indonesia, the Philippines and Brunei. In terms of income, the overseas income of the Company in 2023 has exceeded RMB100 million.Dmall achieved strong revenue growth as its revenue grew by 56.6% from RMB848.2 million in 2021 to RMB1,328.3 million in 2022, and further increased by 19.4% to RMB1,585.4 million in 2023. Dmall’s revenue increased by 22.9% from RMB764.0 million in the six months ended June 30, 2023 to RMB939.2 million in the six months ended June 30, 2024. Dmall has also improved its gross margin during the Track Record Period. Dmall’s gross margins were 20.4%, 38.0%, 35.0%, 36.3% and 38.3% in the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.Mr. Zhang Feng, co-founder, executive Director and president of Dmall said, “We empower retailers to thrive in the digital era and are committed to becoming the world's leading omnichannel retail digital solutions provider. We will uphold the values of "continuous innovation", always strive, constantly strengthen and uphold our own technical barriers and optimize products and services, maintain core competitiveness, continue to provide customers with high-value services, and help customers' business. We look forward to taking the listing as an opportunity to fully leverage our competitive advantages and utilize Hong Kong's unique financing platform to further enhance our strengths and continue to create greater value for our shareholders and investors.”Issued by Porda Havas International Finance Communications Group for and on behalf of Dmall Inc. For further information, please contact:Porda Havas International Finance Communications GroupMS.Fung Kelly(852) 3150 6763kelly.fung@h-advisors.globalMS.Wang Evie(86) 135 2006 8960evie.wang@h-advisors.global Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Edvantage Group Announces FY2024 Annual Results ACN Newswire

Edvantage Group Announces FY2024 Annual Results

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.
More